2026-01-26 - Analysis Report
**Company Overview:**
Albemarle is a US-based chemical company specializing in lithium, bromine, and other chemical products.

**Return Rate Comparison:**

|  | Cumulative Return | Difference | Relative Divergence |
| --- | --- | --- | --- |
| Review Stock (ALB) | 95.95% |  |  |
| Comparison Stock (VOO) | 126.41% | -30.46% | 34.10% |

**Alpha, Beta Analysis:**
| Year       | CAGR | MDD  | Alpha | Beta | Capital (B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | -12.0% | 31.1% | -24.0% | 1.2 | 9.1B |
| 2017-2019  | -43.0% | 31.4% | -68.0% | 1.2 | 8.6B |
| 2018-2020  | 53.0% | 44.4% | 29.0% | 1.2 | 17.4B |
| 2019-2021  | 172.0% | 44.4% | 106.0% | 1.3 | 27.5B |
| 2020-2022  | 125.0% | 44.4% | 118.0% | 1.3 | 25.5B |
| 2021-2023  | -61.0% | 62.2% | -82.0% | 1.5 | 17.0B |
| 2022-2024  | -162.0% | 73.6% | -192.0% | 1.5 | 10.1B |
| 2023-2025  | -142.0% | 77.8% | -217.0% | 1.8 | 16.6B |

**Recent Stock Price Fluctuations:**
|  | Figure        |
| --- | --- |
| Close | $189.51 |
| 5-day SMA | $178.69 |
| 20-day SMA | $162.34 |
| 60-day SMA | $133.45

**Risk and Performance Indicators:**

|  | Indicators          |
| --- | --- |
| Market Risk Indicator (MRI) | 0.70 |
| RSI | 78.12 |
| PPO | 0.70 |
| Hybrid Signal: | Buy |
| Risk Level: | Medium |
| Expected Return (%) | -52.90% |

**Recent News & Significant Events:**
1. Is Albemarle (ALB) Still Attractively Priced After Its Strong 1 Year Share Price Rally
2. Has Albemarle (ALB) Run Too Far After Its 1-Year 117.9% Share Price Surge
3. 'Influx Of Investor Interest' On Lithium Sends Albemarle To 2-Year Highs
4. 2026 Rebound? This High-Voltage Lithium Stock Could Have An Explosive Snapback
5. ALB Stock Surges: Is It Time to Buy?
6. Albemarle (ALB) Receives Four Analyst Price Target Upgrades to $210

**Analyst Opinions:**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.15 (~Buy)
- Opinions: 23
- Target Price (avg/high/low): 165.06 / 210.00 / 80.00

**Recent Earnings Analysis:**
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-11-05 | -1.72 | 1.31 B$ |
| 2025-08-04 | -0.16 | 1.33 B$ |
| 2025-04-30 | 0 | 1.08 B$ |
| 2024-11-06 | -9.45 | 1.35 B$ |
| 2025-11-05 | -9.45 | 1.35 B$ |



**Revenue and Profitability:**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $1.31B | 8.99% |
| 2025-06-30 | $1.33B | 14.80% |
| 2025-03-31 | $1.08B | 14.51% |
| 2024-12-31 | $1.23B | 11.22% |
| 2024-09-30 | $1.35B | -7.68% |

**Capital and Profitability:**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $10.00B | -1.61% |
| 2025-06-30 | $10.24B | 0.22% |
| 2025-03-31 | $10.03B | 0.41% |
| 2024-12-31 | $9.96B | 0.76% |
| 2024-09-30 | $10.24B | -10.44% |

**Comprehensive Analysis:**

*   Albemarle's return rate is lower than the S&P 500's return rate, with a difference of -30.46% as of the last data point.
*   The company's cumulative return over the past period is 95.95%, while the comparison stock (S&P 500) has a cumulative return of 126.41%.
*   Alpha and Beta analysis shows varying performance across different periods, with the highest Alpha at 106% in the 2019-2021 period and the lowest at -217% in the 2023-2025 period.
*   The 5-day SMA, 20-day SMA, and 60-day SMA are decreasing, indicating a possible downtrend in the stock price.
*   RSI and PPO indicators suggest that the stock is slightly overbought, and the Hybrid Signal is 'Buy'.
*   Expected Return is -52.90%, indicating a high risk of investment.
*   Analyst opinions are mixed, with 23 opinions leaning towards a 'Buy' with an average target price of $165.06.
*   Recent earnings analysis shows fluctuating EPS and revenue figures, with a significant decline in EPS in the latest quarter.
*   The revenue and profitability analysis shows mixed results, with high profit margins in some quarters but a negative profit margin in one quarter.
*   Equity and ROE data shows fluctuating figures, with a significant decline in ROE in the latest quarter.

**Recommendation:** Based on the analysis, it is recommended to exercise caution when investing in Albemarle due to the high risk of investment indicated by the negative Expected Return and fluctuating earnings figures.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.